Falsified Medicines: MHRA publishes Class 4 FMD Medicines Information
Recommendation
9 September 2025
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
Register now for ECA's GMP Newsletter
The Medicines and Healthcare products Regulatory Agency (MHRA) is currently investigating an incident where several medicines appear to have left the legal supply chain and have then been re-introduced via WDA(H) 50340 HMS Wholesale Limited. This license has since then been terminated.
In a Falsified Medicines Directive (FMD) Alert published 19 March 2020, the MHRA says that "the products do appear to be genuine with legitimate batch numbers. These products are thought to have been stolen from the legitimate supply chain in early 2019 and reintroduced into the supply chain between May and August 2019. This means that the correct transport and storage conditions cannot be guaranteed and while unlikely, could impact their effectiveness."
Only the batch numbers mentioned in appendix 1 of the PDF are within the scope of this alert. You can download the document here.
Related GMP News
15.07.2025New Swissmedic Technical Interpretation on Returns of Medicinal Products
15.07.2025Two new GDP Non-Compliance Reports from Austria and Ireland published in the EudraGMDP database
15.07.2025Reminder: Participate in the GDP Implementation Survey until 31 July 2025
15.07.2025PDA Publishes Results of Transportation Validation Benchmarking Survey
10.06.2025Stimuli Article Proposes Revision of USP Definition of Controlled Room Temperature (CRT)
10.06.2025New MHRA Blog Post: Supplying Medicines to Ships, Aircraft and Oil Platforms